Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 2, 2016, Pages 528-534

  Kuribayashi, Kozo ^a   Funaguchi, Norihiko ^b   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b ASAHI UNIVERSITY   (Japan)

Author keywords

Cisplatin; cytotoxic agents; driver mutations; paclitaxel; personalized therapy

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NAVELBINE; NECITUMUMAB; RAMUCIRUMAB; TUMOR MARKER;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); GENE MUTATION; HUMAN; INOPERABLE CANCER; JAPAN; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GENETICS; LUNG NEOPLASMS; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84980011875     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.174185     Document Type: Review

References (30)

1. Sawabata N, Asamura H, Goya T, Mori M, Nakanishi Y, Eguchi K, et al. Japanese Lung Cancer Registry Study: First prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010;5: 1369-75.
2. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-smallcell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer 2014;14: 535-46.
3. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12: 175-80.
4. Non-mall Cell Lung Cancer Collaborative Group.Chemotherapyandsupportivecareversussupportivecarealoneforadvancednon-smallcelllungcancer.CochraneDatabaseSystRev2010;12:CD007309.Doi 10 1002/14651858
5. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19: 3210-8.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002;346: 92-8.
7. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-smallcell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005;47: 69-80.
8. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabinewith cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26: 3543-51.
9. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18: 317-23.
10. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22: 254-61.
11. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: Results of a West Japan oncology group study. J Clin Oncol 2010;28: 5240-6.
12. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 2015;26: 1401-8.
13. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12: 1317-24.
14. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30: 2055-62.
15. Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, et al. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24: 314-21.
16. The Japan Lung Cancer Society. First-line chemotherapy of NSCLC (stage IV). The Japan Lung Cancer Society Guidelines: Advanced NSCLC. Tokyo: Kanehara & Co., Ltd.; 2014.
17. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24: 20-30.
18. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007;99: 847-57.
19. Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol 2013;24: 1326-31.
20. Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2013;81: 97-101.
21. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373: 1525-31.
22. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 2014;83: 211-8.
23. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16: 763-74.
24. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med 2015;373: 123-35.
25. Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, et al. Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33: 1266-7. [Suppl; Abstr 8027].
26. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28: 780-7.
27. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384: 665-73.
28. Hosomi Y, Yoh K, Kasahara K, Yamada K, Takahashi T, Tanaka K, et al. Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan. J Clin Oncol 2015;33. [Suppl; abstr 8054].
29. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343: 342-50.
30. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16: 897-907.